Open Orphan PLC said Wednesday that its hVIVO subsidiary has signed a 7.3 million pounds ($9.1 million) influenza human challenge study contract with …
Read more on pharmprom.net
Pharmaceutical Industry in Russia flipped this story into PharmProm.Net•38d